Issue 76, 2013
From the journal:

Chemical Communications

An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors – potential therapeutics in cancer and neurodegeneration†

Russell R. A. Kitsona  and  Christopher J. Moody*a  

* Corresponding authors

a School of Chemistry, University of Nottingham, University Park, Nottingham, UK
E-mail: c.j.moody@nottingham.ac.uk
Fax: +44 (0)115 951 3564

Abstract

19-Substituted geldanamycin derivatives are efficient Hsp90 inhibitors, without the toxicity associated with the other benzoquinone ansamycins, thus giving them potential for use as molecular therapeutics in cancer and neurodegeneration. Here a new method of synthesising these important compounds is reported, eliminating the need for toxic metals and metalloids.

Graphical abstract: An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors – potential therapeutics in cancer and neurodegeneration

About
Cited by
Related
Download options Please wait...

Supplementary files

Article information

DOI
https://doi.org/10.1039/C3CC43457E
Article type
Communication
Submitted
09 May 2013
Accepted
10 Jun 2013
First published
10 Jun 2013
This article is Open Access
Creative Commons BY license

Chem. Commun., 2013,49, 8441-8443

Permissions

Request permissions

An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors – potential therapeutics in cancer and neurodegeneration

R. R. A. Kitson and C. J. Moody, Chem. Commun., 2013, 49, 8441 DOI: 10.1039/C3CC43457E

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements